Literature DB >> 19344420

Replicative potential of human natural killer cells.

Hiroyuki Fujisaki1, Harumi Kakuda, Chihaya Imai, Charles G Mullighan, Dario Campana.   

Abstract

The replicative potential of human CD56(+) CD3(-) natural killer (NK) cells is unknown. We found that by exposing NK cells to the leukaemic cell line K562 genetically modified to express 4-1BB ligand and interleukin 15 (K562-mb15-41BBL), they expanded for up to 30 population doublings, achieving numbers that ranged from 1.6 x 10(5) to 1.2 x 10(11)% (median, 5.9 x 10(6)%; n = 7) of those originally seeded. However, NK cells eventually became unresponsive to stimulation and died. Their demise could be suppressed by enforcing the expression of the human telomerase reverse transcriptase gene (TERT). TERT-overexpressing NK cells continued to proliferate in response to K562-mb15-41BBL stimulation for more than 1 year of culture, while maintaining a normal karyotype and genotype. Long-lived NK cells had high cytotoxicity against myeloid and T-lineage leukaemic cells. They remained susceptible to genetic manipulation, becoming highly cytotoxic to B-lineage leukaemic cells after expression of anti-CD19 signaling receptors. Thus, human NK cells have a replicative potential similar to that of T lymphocytes and their lifespan can be significantly prolonged by an increase in TERT activity. We suggest that the methods described here should have many applications in studies of NK cell biology and NK cell-based therapies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19344420      PMCID: PMC2776622          DOI: 10.1111/j.1365-2141.2009.07667.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  30 in total

1.  Role of monocytes in the expansion of human activated natural killer cells.

Authors:  J S Miller; S Oelkers; C Verfaillie; P McGlave
Journal:  Blood       Date:  1992-11-01       Impact factor: 22.113

2.  Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells.

Authors:  Chihaya Imai; Shotaro Iwamoto; Dario Campana
Journal:  Blood       Date:  2005-03-08       Impact factor: 22.113

Review 3.  NK cell recognition.

Authors:  Lewis L Lanier
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

Review 4.  Replicative senescence of T cells: does the Hayflick Limit lead to immune exhaustion?

Authors:  R B Effros; G Pawelec
Journal:  Immunol Today       Date:  1997-09

5.  Preferential proliferation of natural killer cells among peripheral blood mononuclear cells cocultured with B lymphoblastoid cell lines.

Authors:  B Perussia; C Ramoni; I Anegon; M C Cuturi; J Faust; G Trinchieri
Journal:  Nat Immun Cell Growth Regul       Date:  1987

6.  A potential role for interleukin-15 in the regulation of human natural killer cell survival.

Authors:  W E Carson; T A Fehniger; S Haldar; K Eckhert; M J Lindemann; C F Lai; C M Croce; H Baumann; M A Caligiuri
Journal:  J Clin Invest       Date:  1997-03-01       Impact factor: 14.808

7.  Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.

Authors:  Jeffrey S Miller; Yvette Soignier; Angela Panoskaltsis-Mortari; Sarah A McNearney; Gong H Yun; Susan K Fautsch; David McKenna; Chap Le; Todd E Defor; Linda J Burns; Paul J Orchard; Bruce R Blazar; John E Wagner; Arne Slungaard; Daniel J Weisdorf; Ian J Okazaki; Philip B McGlave
Journal:  Blood       Date:  2005-01-04       Impact factor: 22.113

8.  Telomere loss, senescence, and genetic instability in CD4+ T lymphocytes overexpressing hTERT.

Authors:  Alexander Röth; Gabriela M Baerlocher; Mike Schertzer; Elizabeth Chavez; Ulrich Dührsen; Peter M Lansdorp
Journal:  Blood       Date:  2005-03-01       Impact factor: 22.113

9.  A model for the differentiation of human natural killer cells. Studies on the in vitro activation of Leu-11+ granular lymphocytes with a natural killer-sensitive tumor cell, K562.

Authors:  J H Phillips; L L Lanier
Journal:  J Exp Med       Date:  1985-06-01       Impact factor: 14.307

View more
  38 in total

1.  Natural killer cell engineering for cellular therapy of cancer.

Authors:  D R Shook; D Campana
Journal:  Tissue Antigens       Date:  2011-12

Review 2.  Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens.

Authors:  Richard W Childs; Mattias Carlsten
Journal:  Nat Rev Drug Discov       Date:  2015-05-22       Impact factor: 84.694

3.  Cytokines as Adjuvants for Vaccine and Cellular Therapies for Cancer.

Authors:  Christian M Capitini; Terry J Fry; Crystal L Mackall
Journal:  Am J Immunol       Date:  2009-01-01

Review 4.  Clinical utility of natural killer cells in cancer therapy and transplantation.

Authors:  David A Knorr; Veronika Bachanova; Michael R Verneris; Jeffrey S Miller
Journal:  Semin Immunol       Date:  2014-03-05       Impact factor: 11.130

5.  HLA-DR+ NK cells are mostly characterized by less mature phenotype and high functional activity.

Authors:  Sofya A Erokhina; Maria A Streltsova; Leonid M Kanevskiy; William G Telford; Alexander M Sapozhnikov; Elena I Kovalenko
Journal:  Immunol Cell Biol       Date:  2017-12-19       Impact factor: 5.126

6.  Cytotoxicity of activated natural killer cells against pediatric solid tumors.

Authors:  Duck Cho; David R Shook; Noriko Shimasaki; Yu-Hsiang Chang; Hiroyuki Fujisaki; Dario Campana
Journal:  Clin Cancer Res       Date:  2010-06-11       Impact factor: 12.531

Review 7.  Bringing natural killer cells to the clinic: ex vivo manipulation.

Authors:  Richard W Childs; Maria Berg
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2013

8.  Transfer of Her-2/neu specificity into cytokine-induced killer (CIK) cells with RNA encoding chimeric immune receptor (CIR).

Authors:  Sung Hee Yoon; Jin Myung Lee; Sun-Je Woo; Min-Ji Park; Jung-Sun Park; Hye-Sung Kim; Mi-Young Park; Hyun-Jung Sohn; Tai-Gyu Kim
Journal:  J Clin Immunol       Date:  2009-06-11       Impact factor: 8.317

9.  Membrane-bound interleukin-21 and CD137 ligand induce functional human natural killer cells from peripheral blood mononuclear cells through STAT-3 activation.

Authors:  X Wang; D A Lee; Y Wang; L Wang; Y Yao; Z Lin; J Cheng; S Zhu
Journal:  Clin Exp Immunol       Date:  2013-04       Impact factor: 4.330

10.  Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy.

Authors:  Yin Liu; Hong-Wei Wu; Michael A Sheard; Richard Sposto; Srinivas S Somanchi; Laurence J N Cooper; Dean A Lee; Robert C Seeger
Journal:  Clin Cancer Res       Date:  2013-02-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.